Broadwood Partners, L.P. Acquires 34,296 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 34,296 shares of STAAR Surgical stock in a transaction dated Tuesday, March 25th. The shares were purchased at an average cost of $17.44 per share, for a total transaction of $598,122.24. Following the completion of the transaction, the insider now owns 12,319,691 shares of the company’s stock, valued at approximately $214,855,411.04. This represents a 0.28 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The shares were acquired at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were acquired at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The stock was bought at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The shares were bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The stock was bought at an average cost of $21.50 per share, with a total value of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. purchased 21,155 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.46 per share, for a total transaction of $453,986.30.

STAAR Surgical Stock Up 0.6 %

Shares of NASDAQ STAA opened at $17.57 on Thursday. The business’s 50 day moving average price is $19.61 and its two-hundred day moving average price is $25.37. The company has a market cap of $866.64 million, a PE ratio of -42.85 and a beta of 0.66. STAAR Surgical has a twelve month low of $13.50 and a twelve month high of $52.68.

Analysts Set New Price Targets

STAA has been the subject of a number of research reports. Canaccord Genuity Group decreased their price objective on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a report on Thursday, February 13th. William Blair downgraded shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. BTIG Research cut shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Stephens reiterated an “equal weight” rating and issued a $17.00 price target on shares of STAAR Surgical in a research note on Tuesday, March 18th. Finally, Piper Sandler reduced their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, STAAR Surgical presently has a consensus rating of “Hold” and a consensus target price of $25.29.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Resona Asset Management Co. Ltd. bought a new position in STAAR Surgical during the fourth quarter worth $36,411,000. Vanguard Group Inc. boosted its holdings in shares of STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after buying an additional 319,441 shares during the period. Yunqi Capital Ltd boosted its holdings in shares of STAAR Surgical by 48.9% during the 4th quarter. Yunqi Capital Ltd now owns 767,413 shares of the medical instruments supplier’s stock worth $18,640,000 after buying an additional 252,113 shares during the period. JPMorgan Chase & Co. grew its stake in STAAR Surgical by 411.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after buying an additional 172,779 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in STAAR Surgical by 25.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock valued at $20,728,000 after acquiring an additional 171,046 shares during the period. 96.70% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.